

LIQUID BIOPSY RESEARCH TOOLS, SERVICES AND DIAGNOSTICS: GLOBAL MARKETS



BIO150A
January 2016

John Bergin
Project Analyst

ISBN: 1-62296-224-9



BCC Research
49 Walnut Park, Building 2
Wellesley, MA 02481 USA
866-285-7215 (toll-free within the USA),
or (+1) 781-489-7301
www.bccresearch.com
information@bccresearch.com

TABLE OF CONTENTS

TOPIC	PAGE NO.
CHAPTER 1 INTRODUCTION	2
STUDY GOALS AND OBJECTIVES	2
REASONS FOR DOING THE STUDY	2
CONTRIBUTION OF THE STUDY AND FOR WHOM	3
SCOPE AND FORMAT	3
METHODOLOGY	4
INFORMATION SOURCES	4
ANALYST'S CREDENTIALS	4
RELATED BCC RESEARCH REPORTS	4
BCC RESEARCH WEBSITE	5
DISCLAIMER	5
CHAPTER 2 EXECUTIVE SUMMARY	7
<i>SUMMARY TABLE GLOBAL LIQUID BIOPSY MARKET BY APPLICATION, THROUGH 2020 (\$ MILLIONS)</i>	7
<i>SUMMARY FIGURE GLOBAL LIQUID BIOPSY MARKET BY APPLICATION, 2014-2020 (\$ MILLIONS)</i>	8
CHAPTER 3 OVERVIEW	11
INTRODUCTION	11
<i>TABLE 1 LIQUID BIOPSY SAMPLE TYPES</i>	11
REPORT SCOPE	12
<i>TABLE 2 LIQUID BIOPSY REPORT SCOPE</i>	12
LIQUID BIOPSY VERSUS TRADITIONAL BIOPSY	12
MARKETS	13
<i>TABLE 3 LIQUID BIOPSY MARKET BY ANALYSIS TYPE, THROUGH 2020 (\$ MILLIONS)</i>	13
GROWTH DRIVING FORCES	14
<i>TABLE 4 GROWTH DRIVING FORCES</i>	14
KEY TRENDS	15
<i>TABLE 5 KEY TRENDS IN LIQUID BIOPSY</i>	15
INDUSTRY	16
<i>TABLE 6 SINGLE CELL ANALYSIS INDUSTRY SUBSECTORS</i>	16
CHAPTER 4 TECHNOLOGIES	18
LIQUID BIOPSY BIOMARKERS	18
<i>TABLE 7 LIQUID BIOPSY BIOMARKER CLASSES</i>	18
CANCER GENOMICS	19
<i>FIGURE 1 HOW CANCER GENOMICS DRIVES LIQUID BIOPSY</i>	19
<i>TABLE 8 SINGLE CELL ANALYSIS TO IDENTIFY CANCER DRIVER MUTATIONS</i>	20
<i>TABLE 9 GENOMICS-BASED ONCOLOGY WORKFLOW</i>	21
NONINVASIVE PRENATAL TESTING	22
<i>TABLE 10 CELL-FREE DNA ANALYSIS APPROACHES</i>	23
CIRCULATING TUMOR CELL (CTC) TECHNOLOGIES	24
<i>TABLE 11 UNIQUE TECHNICAL CHALLENGES OF CTC CAPTURE AND ANALYSIS</i>	24
CTC WORKFLOW	25
<i>TABLE 12 CTC WORKFLOW</i>	25

TOPIC	PAGE NO.
CELL ISOLATION TECHNOLOGIES	26
<i>TABLE 13 CELL DIFFERENTIATORS</i>	26
<i>TABLE 14 CELL ISOLATION TECHNOLOGIES</i>	27
CTC SAMPLE PREPARATION TECHNOLOGIES	28
<i>TABLE 15 CTC SAMPLE PREPARATION TECHNOLOGIES</i>	29
CTC DOWNSTREAM ANALYSIS TECHNOLOGIES	29
<i>TABLE 16 SINGLE CELL ANALYSIS TECHNOLOGIES</i>	30
COMPARISON OF LIQUID BIOPSY WITH CONVENTIONAL BIOPSY	30
CANCER TESTING	31
<i>TABLE 17 ESTIMATED ANNUAL BIOPSY PROCEDURES PERFORMED IN THE U.S. FOR SELECTED CANCERS</i>	31
<i>TABLE 18 MAIN RISKS FOR NEEDLE-BASED TISSUE BIOPSIES</i>	31
<i>TABLE 19 FACTORS IN TISSUE BIOPSY</i>	33
PRENATAL TESTING	33
<i>TABLE 20 INVASIVE PRENATAL TESTING TECHNOLOGIES</i>	34
<i>TABLE 21 INVASIVE VERSUS NONINVASIVE PRENATAL TECHNOLOGIES</i>	35
CHAPTER 5 LIQUID BIOPSY INITIATIVES	37
KEY COLLABORATIVE INITIATIVES	37
<i>TABLE 22 KEY LIQUID BIOPSY RESEARCH AND DEVELOPMENT PROGRAMS</i>	37
CAMBRIDGE SINGLE CELL ANALYSIS CORE FACILITY	37
CANCER-ID	38
CTC TRAP CONSORTIUM	38
EARLY CANCER DETECTION CONSORTIUM	38
HEMATOLOGIC ONCOLOGY CONSORTIUM	38
NATIONAL CENTER FOR SINGLE CELL BIOLOGY	39
PRECISION MEDICINE INITIATIVE	39
SINGLE CELL ANALYSIS PROGRAM	39
WORLDWIDE INNOVATIVE NETWORKING (WIN) CONSORTIUM	40
CHAPTER 6 LIQUID BIOPSY APPLICATIONS	42
INTRODUCTION	42
<i>TABLE 23 SOURCE OF FOREIGN BIOMARKERS FOR LIQUID BIOPSY APPLICATIONS</i>	42
CANCER APPLICATIONS	42
PRECISION MEDICINE	42
<i>TABLE 24 PERSONALIZED MEDICINE DRIVEN BY CANCER COMMON GENETIC MUTATIONS</i>	42
CANCER BIOMARKER STATUS	43
<i>TABLE 25 CANCER LIQUID BIOPSY BIOMARKER CLINICAL STATUS</i>	44
CANCER MARKET SEGMENTS	45
<i>TABLE 26 CANCER LIQUID BIOPSY MARKET SEGMENTS</i>	45
REPRODUCTIVE HEALTH APPLICATIONS	47
<i>TABLE 27 NIPT AS A SCREENING APPLICATION</i>	47
<i>TABLE 28 ETHICAL ISSUES ASSOCIATED WITH PRENATAL AND NEWBORN SCREENING</i>	48
TRANSPLANT DIAGNOSTICS APPLICATIONS	49
<i>TABLE 29 TRANSPLANT DIAGNOSTICS APPLICATIONS</i>	49

TOPIC	PAGE NO.
CHAPTER 7 LIQUID BIOPSY INDUSTRY	51
INTRODUCTION	51
<i>TABLE 30 KEY SEGMENTS WITHIN THE LIQUID BIOPSY INDUSTRY</i>	51
NGS INSTRUMENT INDUSTRY	52
<i>TABLE 31 NEXT-GENERATION SEQUENCING INSTRUMENT COMPANIES SUMMARY</i>	52
DROPLET DIGITAL PCR (DDPCR) INDUSTRY	55
<i>TABLE 32 ADVANTAGES OF DDPCR FOR SINGLE CELL ANALYSIS</i>	55
<i>TABLE 33 DDPCR INDUSTRY</i>	56
TARGET ENRICHMENT AND AMPLIFICATION INDUSTRY	56
<i>TABLE 34 SINGLE CELL TARGET ENRICHMENT INDUSTRY</i>	57
SINGLE CELL DNA POLYMERASE INDUSTRY	58
<i>TABLE 35 SINGLE CELL DNA POLYMERASE INDUSTRY</i>	58
NONINVASIVE PRENATAL TESTING INDUSTRY	59
<i>TABLE 36 NGS NIPT INDUSTRY</i>	60
<i>TABLE 37 GLOBAL NIPT MARKET BY REGION AND COMPANY BY NUMBER OF TESTS, 2015</i>	64
<i>TABLE 38 GERMANY NGS-BASED NONINVASIVE PRENATAL DIAGNOSTIC COMPANIES, 2015</i>	65
LIQUID BIOPSY INDUSTRY	67
<i>TABLE 39 LIQUID BIOPSY INDUSTRY COMPANY FOCUS</i>	68
CHAPTER 8 ACQUISITIONS AND STRATEGIC ALLIANCES	77
ACQUISITIONS	77
<i>TABLE 40 LIQUID BIOPSY INDUSTRY ACQUISITIONS, JANUARY 2013-OCTOBER 2015</i>	77
STRATEGIC ALLIANCES	80
<i>TABLE 41 SINGLE CELL INDUSTRY STRATEGIC ALLIANCES, JANUARY 2013-OCTOBER 2015</i>	80
CHAPTER 9 MARKETS	90
GROWTH DRIVING FORCES	90
<i>TABLE 42 LIQUID BIOPSY MARKET GROWTH DRIVING FORCES</i>	90
LIQUID BIOPSY MARKET	91
BY INDICATION	91
<i>TABLE 43 LIQUID BIOPSY MARKET BY INDICATION, THROUGH 2020 (\$ MILLIONS)</i>	91
BY BIOMARKER TYPE	92
<i>TABLE 44 LIQUID BIOPSY MARKET BY BIOMARKER TYPE, THROUGH 2020 (\$ MILLIONS)</i>	92
BY ANALYSIS PLATFORM	92
<i>TABLE 45 LIQUID BIOPSY MARKET BY ANALYSIS PLATFORM, THROUGH 2020 (\$ MILLIONS)</i>	93
BY ANALYSIS PURPOSE	93
<i>TABLE 46 LIQUID BIOPSY MARKET BY ANALYSIS PURPOSE, THROUGH 2020 (\$ MILLIONS)</i>	93
NONINVASIVE PRENATAL TESTING MARKET	94
<i>TABLE 47 NIPT MARKET BY RISK TYPE, THROUGH 2020 (\$ MILLIONS)</i>	95
<i>TABLE 48 NIPT MARKET BY ANALYSIS PURPOSE, THROUGH 2020 (\$ MILLIONS)</i>	96
<i>TABLE 49 NIPT MARKET BY BIOMARKER CLASS, THROUGH 2020 (\$ MILLIONS)</i>	98
<i>TABLE 50 NIPT MARKET BY ANALYSIS METHOD, THROUGH 2020 (\$ MILLIONS)</i>	99
<i>TABLE 51 NGS NIPT MARKET BY INSTRUMENT TYPE, THROUGH 2020 (\$ MILLIONS)</i>	100

TOPIC	PAGE NO.
CANCER MARKET	100
<i>TABLE 52 CANCER MARKET BY INDICATION, THROUGH 2020 (\$ MILLIONS)</i>	100
<i>TABLE 53 CANCER MARKET BY ANALYSIS PURPOSE, THROUGH 2020 (\$ MILLIONS)</i>	102
<i>TABLE 54 EARLY CANCER DETECTION (MM/NO.)</i>	103
<i>TABLE 55 CANCER MARKET BY BIOMARKER CLASS, THROUGH 2020 (\$ MILLIONS)</i>	105
<i>TABLE 56 CANCER MARKET BY ANALYSIS METHOD, THROUGH 2020 (\$ MILLIONS)</i>	106
CTC CANCER MARKET	107
<i>TABLE 57 CTC CANCER MARKET BY INDICATION, THROUGH 2020 (\$ MILLIONS)</i>	107
<i>TABLE 58 CTC CANCER MARKET BY ANALYSIS METHOD, THROUGH 2020 (\$ MILLIONS)</i>	109
CFDNA CANCER MARKET	110
<i>TABLE 59 CFDNA CANCER MARKET BY INDICATION, THROUGH 2020 (\$ MILLIONS)</i>	110
<i>TABLE 60 CFDNA CANCER MARKET BY ANALYSIS METHOD, THROUGH 2020 (\$ MILLIONS)</i>	112
EV CANCER MARKET	113
<i>TABLE 61 EV CANCER MARKET BY INDICATION, THROUGH 2020 (\$ MILLIONS)</i>	113
<i>TABLE 62 EV CANCER MARKET BY ANALYSIS METHOD, THROUGH 2020 (\$ MILLIONS)</i>	114
TRANSPLANT MARKET	115
<i>TABLE 63 TRANSPLANT MARKET BY ORGAN TYPE, THROUGH (\$ MILLIONS)</i>	115
<i>TABLE 64 U.S. LIQUID BIOPSY TRANSPLANT MARKET (PROCEDURES PER YEAR/NUMBER OF PATIENTS)</i>	116
<i>TABLE 65 TRANSPLANT MARKET BY ANALYSIS PURPOSE, THROUGH 2020 (\$ MILLIONS)</i>	117
<i>TABLE 66 TRANSPLANT MARKET BY BIOMARKER CLASS, THROUGH 2020 (\$ MILLIONS)</i>	117
<i>TABLE 67 TRANSPLANT MARKET BY ANALYSIS METHOD, THROUGH 2020 (\$ MILLIONS)</i>	118
LIQUID BIOPSY MARKET BY REGION	119
<i>TABLE 68 LIQUID BIOPSY MARKET BY REGION, THROUGH 2020 (\$ MILLIONS)</i>	119
<i>TABLE 69 CANCER MARKET BY REGION, THROUGH 2020 (\$ MILLIONS)</i>	120
<i>TABLE 70 NIPT MARKET BY REGION, THROUGH 2020 (\$ MILLIONS)</i>	120
<i>TABLE 71 TRANSPLANT MARKET BY REGION, THROUGH 2020 (\$ MILLIONS)</i>	122
CHAPTER 10 PATENTS	125
CIRCULATING TUMOR CELL PATENTS	125
<i>TABLE 72 CTC PATENTS, 2005-2015</i>	125
CELL-FREE DNA PATENTS	126
<i>TABLE 73 CELL-FREE DNA PATENTS, 2005-2015</i>	126
CHAPTER 11 COMPANY PROFILES	128
AFFYMETRIX	128
AGILENT TECHNOLOGIES INC.	128
ANGLE PLC	130
ANNOROAD GENE TECHNOLOGY	131
APOCELL	132
ASURAGEN INC.	132
AVIVA BIOSCIENCES	133
BECTON, DICKINSON AND CO.	134

TOPIC	PAGE NO.
BERRY GENOMICS CO. LTD.	135
BGI SHENZHEN	136
BIOCARTIS NV	137
BIOCEPT INC.	138
BIOFLUIDICA INC.	139
BIO-RAD LABORATORIES INC.	140
BOREAL GENOMICS	140
CELL MICROSYSTEMS INC.	141
CELLSEE DIAGNOSTICS INC.	141
CELLULAR RESEARCH INC.	142
CHRONIX BIOMEDICAL	143
CIRCULOGENE THERANOSTICS	143
CIRCULOMICS INC.	144
CLONTECH LABORATORIES INC.	144
CYNVENIO BIOSYSTEMS INC.	144
CYTOTRACK APS	145
DANAHER CORP.	145
DIAGNOLOGIX LLC	146
DNA ELECTRONICS LTD.	147
EPIC SCIENCES	148
EXOSOME DIAGNOSTICS INC.	148
FLUIDIGM CORP.	149
FOUNDATION MEDICINE	150
FLUXION BIOSCIENCES INC.	151
GATC BIOTECH AG	151
GE HEALTHCARE	152
GENOMIC HEALTH INC.	153
GIGAGEN INC.	154
GOOD START GENETICS INC.	154
GUARDANT HEALTH INC.	155
HTG MOLECULAR DIAGNOSTICS INC.	156
ILLUMINA INC.	157
<i>TABLE 74 NEW PLATFORMS INTRODUCED BY ILLUMINA, 2015</i>	157
JOHNSON & JOHNSON	161
KELLBENX INC.	162
LABORATORY CORP. OF AMERICA INC.	163
MDX HEALTH INC.	164
MERCK KGAA	165
MYRIAD GENETICS INC.	165
NATERA INC.	167
NEOGENOMICS INC.	168
NEW ENGLAND BIOLABS	169
NEW ONCOLOGY AG	169
NUGEN TECHNOLOGIES INC.	170
OXFORD GENE TECHNOLOGY	171
OXFORD NANOPORE TECHNOLOGIES LTD.	171
PACIFIC BIOSCIENCES OF CALIFORNIA INC.	172

TOPIC	PAGE NO.
PATHWAY GENOMICS CORP.	174
PERSONAL GENOME DIAGNOSTICS INC.	175
PROVISTA DIAGNOSTICS INC.	176
QIAGEN NV	176
RAINDANCE TECHNOLOGIES INC.	178
RARECELLS SAS	179
RARECYTE INC.	179
RESOLUTION BIOSCIENCE INC.	179
ROCHE HOLDING AG	180
<i>TABLE 75 COMMERCIAL SEQUENCER COMPETITIVE POSITIONING</i>	181
RUBICON GENOMICS	183
SALVEO DX	183
SCREENCELL	183
SENGENICS INTERNATIONAL PTE LTD.	184
SEQUENOM INC.	184
SILICON BIOSYSTEMS	186
SPHERE FLUIDICS LTD.	186
STRAND LIFE SCIENCES	187
STRATEC BIOMEDICAL AG	187
SYGNIS AG	187
SYSMEX INOSTICS	188
TAI DIAGNOSTICS INC.	188
THERMO FISHER SCIENTIFIC INC.	188
THORNE DIAGNOSTICS INC.	190
TROVAGENE INC.	190
TRANSGENOMIC INC.	191
VITATEX INC.	191
WAFERGEN BIO-SYSTEMS INC.	192
<i>TABLE 76 WAFERGEN STRATEGIC ALLIANCES</i>	192
XCELL BIOSCIENCES INC.	193
YIKON GENOMICS CO. LTD.	193
ZEPHYRUS BIOSCIENCES INC.	194

LIST OF TABLES

TABLE HEADING	PAGE NO.
SUMMARY TABLE GLOBAL LIQUID BIOPSY MARKET BY APPLICATION, THROUGH 2020 (\$ MILLIONS)	7
TABLE 1 LIQUID BIOPSY SAMPLE TYPES	11
TABLE 2 LIQUID BIOPSY REPORT SCOPE	12
TABLE 3 LIQUID BIOPSY MARKET BY ANALYSIS TYPE, THROUGH 2020 (\$ MILLIONS)	13
TABLE 4 GROWTH DRIVING FORCES	14
TABLE 5 KEY TRENDS IN LIQUID BIOPSY	15
TABLE 6 SINGLE CELL ANALYSIS INDUSTRY SUBSECTORS	16
TABLE 7 LIQUID BIOPSY BIOMARKER CLASSES	18
TABLE 8 SINGLE CELL ANALYSIS TO IDENTIFY CANCER DRIVER MUTATIONS	20
TABLE 9 GENOMICS-BASED ONCOLOGY WORKFLOW	21
TABLE 10 CELL-FREE DNA ANALYSIS APPROACHES	23
TABLE 11 UNIQUE TECHNICAL CHALLENGES OF CTC CAPTURE AND ANALYSIS	24
TABLE 12 CTC WORKFLOW	25
TABLE 13 CELL DIFFERENTIATORS	26
TABLE 14 CELL ISOLATION TECHNOLOGIES	27
TABLE 15 CTC SAMPLE PREPARATION TECHNOLOGIES	29
TABLE 16 SINGLE CELL ANALYSIS TECHNOLOGIES	30
TABLE 17 ESTIMATED ANNUAL BIOPSY PROCEDURES PERFORMED IN THE U.S. FOR SELECTED CANCERS	31
TABLE 18 MAIN RISKS FOR NEEDLE-BASED TISSUE BIOPSIES	31
TABLE 19 FACTORS IN TISSUE BIOPSY	33
TABLE 20 INVASIVE PRENATAL TESTING TECHNOLOGIES	34
TABLE 21 INVASIVE VERSUS NONINVASIVE PRENATAL TECHNOLOGIES	35
TABLE 22 KEY LIQUID BIOPSY RESEARCH AND DEVELOPMENT PROGRAMS	37
TABLE 23 SOURCE OF FOREIGN BIOMARKERS FOR LIQUID BIOPSY APPLICATIONS	42
TABLE 24 PERSONALIZED MEDICINE DRIVEN BY CANCER COMMON GENETIC MUTATIONS	42
TABLE 25 CANCER LIQUID BIOPSY BIOMARKER CLINICAL STATUS	44
TABLE 26 CANCER LIQUID BIOPSY MARKET SEGMENTS	45
TABLE 27 NIPT AS A SCREENING APPLICATION	47
TABLE 28 ETHICAL ISSUES ASSOCIATED WITH PRENATAL AND NEWBORN SCREENING	48
TABLE 29 TRANSPLANT DIAGNOSTICS APPLICATIONS	49
TABLE 30 KEY SEGMENTS WITHIN THE LIQUID BIOPSY INDUSTRY	51
TABLE 31 NEXT-GENERATION SEQUENCING INSTRUMENT COMPANIES SUMMARY	52
TABLE 32 ADVANTAGES OF DDPCR FOR SINGLE CELL ANALYSIS	55
TABLE 33 DDPCR INDUSTRY	56
TABLE 34 SINGLE CELL TARGET ENRICHMENT INDUSTRY	57
TABLE 35 SINGLE CELL DNA POLYMERASE INDUSTRY	58
TABLE 36 NGS NIPT INDUSTRY	60
TABLE 37 GLOBAL NIPT MARKET BY REGION AND COMPANY BY NUMBER OF TESTS, 2015	64
TABLE 38 GERMANY NGS-BASED NONINVASIVE PRENATAL DIAGNOSTIC COMPANIES, 2015	65
TABLE 39 LIQUID BIOPSY INDUSTRY COMPANY FOCUS	68
TABLE 40 LIQUID BIOPSY INDUSTRY ACQUISITIONS, JANUARY 2013-OCTOBER 2015	77

TABLE HEADING	PAGE NO.
TABLE 41 SINGLE CELL INDUSTRY STRATEGIC ALLIANCES, JANUARY 2013-OCTOBER 2015	80
TABLE 42 LIQUID BIOPSY MARKET GROWTH DRIVING FORCES	90
TABLE 43 LIQUID BIOPSY MARKET BY INDICATION, THROUGH 2020 (\$ MILLIONS)	91
TABLE 44 LIQUID BIOPSY MARKET BY BIOMARKER TYPE, THROUGH 2020 (\$ MILLIONS)	92
TABLE 45 LIQUID BIOPSY MARKET BY ANALYSIS PLATFORM, THROUGH 2020 (\$ MILLIONS)	93
TABLE 46 LIQUID BIOPSY MARKET BY ANALYSIS PURPOSE, THROUGH 2020 (\$ MILLIONS)	93
TABLE 47 NIPT MARKET BY RISK TYPE, THROUGH 2020 (\$ MILLIONS)	95
TABLE 48 NIPT MARKET BY ANALYSIS PURPOSE, THROUGH 2020 (\$ MILLIONS)	96
TABLE 49 NIPT MARKET BY BIOMARKER CLASS, THROUGH 2020 (\$ MILLIONS)	98
TABLE 50 NIPT MARKET BY ANALYSIS METHOD, THROUGH 2020 (\$ MILLIONS)	99
TABLE 51 NGS NIPT MARKET BY INSTRUMENT TYPE, THROUGH 2020 (\$ MILLIONS)	100
TABLE 52 CANCER MARKET BY INDICATION, THROUGH 2020 (\$ MILLIONS)	100
TABLE 53 CANCER MARKET BY ANALYSIS PURPOSE, THROUGH 2020 (\$ MILLIONS)	102
TABLE 54 EARLY CANCER DETECTION (MM/NO.)	103
TABLE 55 CANCER MARKET BY BIOMARKER CLASS, THROUGH 2020 (\$ MILLIONS)	105
TABLE 56 CANCER MARKET BY ANALYSIS METHOD, THROUGH 2020 (\$ MILLIONS)	106
TABLE 57 CTC CANCER MARKET BY INDICATION, THROUGH 2020 (\$ MILLIONS)	107
TABLE 58 CTC CANCER MARKET BY ANALYSIS METHOD, THROUGH 2020 (\$ MILLIONS)	109
TABLE 59 CFDNA CANCER MARKET BY INDICATION, THROUGH 2020 (\$ MILLIONS)	110
TABLE 60 CFDNA CANCER MARKET BY ANALYSIS METHOD, THROUGH 2020 (\$ MILLIONS)	112
TABLE 61 EV CANCER MARKET BY INDICATION, THROUGH 2020 (\$ MILLIONS)	113
TABLE 62 EV CANCER MARKET BY ANALYSIS METHOD, THROUGH 2020 (\$ MILLIONS)	114
TABLE 63 TRANSPLANT MARKET BY ORGAN TYPE, THROUGH (\$ MILLIONS)	115
TABLE 64 U.S. LIQUID BIOPSY TRANSPLANT MARKET (PROCEDURES PER YEAR/NUMBER OF PATIENTS)	116
TABLE 65 TRANSPLANT MARKET BY ANALYSIS PURPOSE, THROUGH 2020 (\$ MILLIONS)	117
TABLE 66 TRANSPLANT MARKET BY BIOMARKER CLASS, THROUGH 2020 (\$ MILLIONS)	117
TABLE 67 TRANSPLANT MARKET BY ANALYSIS METHOD, THROUGH 2020 (\$ MILLIONS)	118
TABLE 68 LIQUID BIOPSY MARKET BY REGION, THROUGH 2020 (\$ MILLIONS)	119
TABLE 69 CANCER MARKET BY REGION, THROUGH 2020 (\$ MILLIONS)	120
TABLE 70 NIPT MARKET BY REGION, THROUGH 2020 (\$ MILLIONS)	120
TABLE 71 TRANSPLANT MARKET BY REGION, THROUGH 2020 (\$ MILLIONS)	122
TABLE 72 CTC PATENTS, 2005-2015	125
TABLE 73 CELL-FREE DNA PATENTS, 2005-2015	126
TABLE 74 NEW PLATFORMS INTRODUCED BY ILLUMINA, 2015	157
TABLE 75 COMMERCIAL SEQUENCER COMPETITIVE POSITIONING	181
TABLE 76 WAFERGEN STRATEGIC ALLIANCES	192

LIST OF FIGURES

FIGURE TITLE	PAGE NO.
SUMMARY FIGURE GLOBAL LIQUID BIOPSY MARKET BY APPLICATION, 2014-2020 (\$ MILLIONS)	8
FIGURE 1 HOW CANCER GENOMICS DRIVES LIQUID BIOPSY	19